Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the
Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the quarter ended June 30, 2002, including an affirmative disclosure that the report has been reviewed consistent with SAS 71, as well as a Form 10-Q for the quarter ended Sept. 30, 2002. Alliance Pharmaceutical had no such recourse. The company announced Oct. 17 its delisting from the exchange for failure to meet certain requirements. The company¹s stock is now being traded on Nasdaq's over-the-counter bulletin board.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.